{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-302608","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2026-07-14T12:30:27+00:00","discovered_at":"2026-07-14T12:35:00.273332+00:00","generated_at":"2026-07-14T12:35:04.603105+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Syndax unveils SNDX-4321 (allosteric EGFRi) and SNDX-62122 (menin inhibitor) at R&D event","bullets":["SNDX-4321: novel mutant-selective allosteric EGFR inhibitor for NSCLC; IND expected by end of 2026, Phase 1 in 2027.","SNDX-62122: first next-gen menin inhibitor from internal library; IND and Phase 1 in MF expected in 2027.","Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26.","Revumenib Phase 1/2 trial in MF expected to initiate in 4Q26 with initial data in H2 2027.","Company highlights late-stage revumenib and axatilimab programs in acute leukemia and chronic GVHD."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-302608","json":"https://secwatch.observer/filing/0001193125-26-302608.json","markdown":"https://secwatch.observer/filing/0001193125-26-302608.md","text":"https://secwatch.observer/filing/0001193125-26-302608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526302608/0001193125-26-302608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526302608/sndx-20260714.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-14T12:35:04.603105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}